Bibliografía Comentada

Ramón Colomer Bosch

Hospital Universitario La Princesa, Madrid
Jefe de la sección de oncología médica.

Tomás Pascual Martínez

Hospital Universitario La Princesa, Madrid
FEA oncología médica

Esta sección está supervisada por el grupo de expertos de Oncobyg. La información recogida en esta web refleja únicamente la opinión del grupo de expertos de Oncobyg, y sus recomendaciones no pretenden sustituir a las directrices de consensos de sociedades médicas o de las guías de tratamiento oncológico vigentes en la actualidad

Cáncer de mama

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.

Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, et al. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22(10):2583-93.

16 de noviembre de 2016


Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2016;34(6):542-9.

16 de noviembre de 2016


Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.

16 de noviembre de 2016


Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer.

Aleix Prat, Maggie Chon U. Cheang, Miguel Martín, Joel S. Parker, Eva Carrasco, Rosalía Caballero, Scott Tyldesley, Karen Gelmon, Philip S. Bernard, Torsten O. Nielsen, and Charles M. Perou. Journal of Clinical Oncology Volume 31, NUMBER 2, January 10 2013

9 de febrero de 2015


Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Mitch Dowsett, Ivana Sestak, Elena Lopez-Knowles, Kalvinder Sidhu, Anita K. Dunbier, J. Wayne Cowens, Sean Ferree, James Storhoff, Carl Schaper, and Jack Cuzick. Journal of Clinical Oncology,  Volumen 31, Number 22, August 1 2013

9 de febrero de 2015


Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff, M. Elizabeth H. Hammond, David G. Hicks, Mitch Dowsett, Lisa M. McShane, Kimberly H. Allison, Donald C. Allred, John M.S. Bartlett, Michael Bilous, Patrick Fitzgibbons, Wedad Hanna, Robert B. Jenkins, Pamela B. Mangu, Soonmyung Paik, Edith A. Perez, Michael F. Press, Patricia A. Spears, Gail H. Vance, Giuseppe Viale, and Daniel F. Hayes. Journal of Clinical Oncology, Volume 31, Number 31, November 1, 2013

9 de febrero de 2015


Predictive inmunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer

D. Generali, W.F. Symmans, A. Berruti and S. B. Fox Journal of the National Cancer Institute Monographs 2011, October

3 de noviembre de 2011


Prognostic value of a combined Estrogen Receptor, Progesterone Receptor, Ki 67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison with the Genomic Health Recurrence Score in Early Breast Cancer

J. Cuzick. M. Dowsett, S. Pineda, C. Wale, J. Salter, E. Quinn, L. Zabaglo, E. Mallon, A.R. Green, I.O. Ellis, A. Howell, A. U. Buzdar and J. F. Forbes. Journal of Clinical Oncology 2011, October 22nd.

3 de noviembre de 2011


Assessment of Ki 67 in Breast Cancer: Recommendations from the International Ki 67 in Breast Cancer Working Group

M. Dowsett, T. Nielsen, R. A´Hern, J. Bartlett, R.C. Coombes, J. Cuzick, M. Ellis, N.L. Henry, J.C. Hugh, T. Lively, L. McShane, S. Paik, F. Penault-Llorca, L.Prudkin, M. Regan, J. Salter, C. Sotiriou, I.E. Smith, G. Viale, J.A. Zujewski, D.F. Hayes Journal of the National Cancer Institute 2011, September 2nd.

3 de noviembre de 2011


Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinical-pathological factors on adjuvant clinical decision-making in women with estrogen receptor-positive (ER+) node-negative breast cancer

J.Albanell, A. González, M. Ruiz-Borrego, E. Alba, J.A. García-Saenz, J.M. Corominas, O. Burgues, V. Furio, A. Rojo, J. Palacios, B. Bermejo, M. Martínez-García, M.L. Limon, A.S. Muñoz, M. Martín, I. Tusquets, F. Rojo, R. Colomer, I. Faull and A. Lluch. Annals of Oncology 2011, June 6th.

3 de noviembre de 2011